Title: Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

Short title: Sex differences and antipsychotics

Journal: CNS Drugs

Authors:

Megan Galbally[1,2] ORCID 0000-0003-3909-1918

Karen Wynter[1,3] ORCID 0000-0003-4620-7691

Dan Siskind[4,5] ORCID 0000-0002-2072-9216

Christoph U. Correll[6,7,8,9] ORCID 0000-0002-7254-5646

Korinne Northwood[4,5] ORCID 0000-0001-6268-547X

Susanna Every-Palmer[10] ORCID 0000-0001-6455-9741

Affiliations:
1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

Address Correspondence to: Professor Megan Galbally, megan.galbally@monash.edu

Supplementary Table 5: Treatment emergent severity indices for validated movement side effect indicators (Baseline to End of Phase) by sex, within each Treatment group

		Women n (%)	Men n (%)	p^4	φ
Olanzapine (n=92 women, 241 men)	Treatment-emergent AIMS severity index value of >= 2	11 (12.0)	28 (11.6)	1.000	-0.005
	Treatment-emergent AIMS severity index value of >= 1	18 (19.6)	45 (18.7)	0.976	-0.010
	Treatment-emergent Barnes global clinical assessment value of >= 3	7 (7.6)	8 (3.3)	0.164	-0.092
	Treatment-emergent Simpson-Angus EPS scale mean score value of >= 1	2 (2.2)	21 (8.7)	0.062	0.115
Perphenazine (n=62 women, 199 men)	Treatment-emergent AIMS severity index value of >= 2	8 (12.9)	33 (16.6)	0.620	0.043
	Treatment-emergent AIMS severity index value of >= 1	15 (24.2)	49 (24.6)	1.000	0.004
	Treatment-emergent Barnes global clinical assessment value of >= 3	7 (11.3)	9 (4.5)	0.102	-0.120
	Treatment-emergent Simpson-Angus EPS scale mean score value of >= 1	5 (8.1)	10 (5.0)	0.558	-0.056
Quetiapine (n=80 women, 254 men)	Treatment-emergent AIMS severity index value of >= 2	6 (7.5)	28 (11.0)	0.486	0.050
	Treatment-emergent AIMS severity index value of >= 1	10 (12.5)	42 (16.5)	0.489	0.048
	Treatment-emergent Barnes global clinical assessment value of >= 3	3 (3.8)	13 (5.1)	0.842	0.027
	Treatment-emergent Simpson-Angus EPS scale mean score value of >= 1	2 (2.5)	10 (3.9)	0.797	0.033
Risperidone (n=88 women, 252 men)	Treatment-emergent AIMS severity index value of >= 2	15 (17.0)	28 (11.1)	0.209	-0.078
	Treatment-emergent AIMS severity index value of >= 1	18 (20.5)	40 (15.9)	0.413	-0.053
	Treatment-emergent Barnes global clinical assessment value of >= 3	8 (9.1)	12 (4.8)	0.221	-0.081
	Treatment-emergent Simpson-Angus EPS scale mean score value of >= 1	5 (5.7)	18 (7.1)	0.823	0.025
Ziprasidone (n=55 women, 129 men)	Treatment-emergent AIMS severity index value of >= 2	7 (12.7)	11 (8.5)	0.544	-0.065
	Treatment-emergent AIMS severity index value of >= 1	6 (10.9)	16 (12.4)	0.970	0.021
	Treatment-emergent Barnes global clinical assessment value of >= 3	2 (3.6)	12 (9.3)	0.306	0.098
	Treatment-emergent Simpson-Angus EPS scale mean score value of >= 1	1 (1.8)	5 (3.9)	0.790	0.053

[1]AIMS: Abnormal Involuntary Movement Scale
[2]BRS: Barnes Rating Scale for Akathisia
[3]EPS: Simpson-Angus Extrapyramidal Side Effects Scale
[4]p-values and effect sizes associated with χ^2 tests